Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Revista De Neurologia|October 13, 2006
[The pathophysiology of migraine. Reflections on the glutamatergic hypothesis]J Gonzalez de la Aleja, J Porta-Etessam, J M Sepulveda-Sanchez, et al.
AJNR. American Journal of Neuroradiology|January 25, 2014
A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomasA Hilario, J M Sepulveda, A Perez-Nuñez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 31, 2016
Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumabA Hilario, J M Sepulveda, A Hernandez-Lain, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 2, 2008
Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgiaJ M Gomez-Arguelles, R Dorado, J M Sepulveda, et al.
Clinical Neuropathology|February 17, 2009
Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysisJ M Sepulveda Sanchez, J C Martinez Montero, R Diez-Lobato, et al.
AJNR. American Journal of Neuroradiology|December 31, 2011
The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomasA Hilario, A Ramos, A Perez-Nuñez, et al.
Cancer Treatment Reviews|January 16, 2021
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near futureM Rey-Cárdenas, F Guerrero-Ramos, A Gómez de Liaño Lista, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 9, 2016
New clinical trials regulation in Spain: analysis of royal decree 1090/2015M Martin Jimenez, A Calvo Ferrandiz, J Aparicio Urtasun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphomaV Moreno, J M Sepulveda, M Vieito, et al.
Pageof 1